ecancer

Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer

Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

30 Sep 2012

Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib

Dr Tony Mok - Chinese University of Hong Kong

29 Sep 2012

Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III MISSION trial

Dr Luis Paz-Ares - Virgen del Rocio University Hospital in Seville, Spain

29 Sep 2012

Tobacco control and prevention through social media

Joan Bottorff – University of British Columbia, Kelowna, Canada

21 Sep 2012

Cancer prevention and epidemiology in Russia

Dr David Zardize – Russian National Cancer Research Centre, Moscow, Russia

20 Jul 2012

Importance of cancer prevention

Prof Murat Tuncer - Hacettepe University, Ankara, Turkey

20 Jul 2012

Epigenetics of cancer and changes in DNA modification in tumours

Prof Manel Esteller – University of Barcelona, Catalonia, Spain

16 Jul 2012

Drug development in small cell and non-small cell lung cancer

Dr Leora Horn - Vanderbilt-Ingram Cancer Center, Nashville, USA

18 Jun 2012

Afatinib delays progression of advanced lung adenocarcinomas

Dr James Yang - National Taiwan University Hospital, Taipei

4 Jun 2012

Routine molecular testing of non-small cell lung cancers in community settings

Dr Thomas Zander - University Hospital Cologne, Germany

4 Jun 2012

Increased progression-free survival in advanced lung cancer with afatinib

Dr James Yang - National Taiwan University Hospital Taipei, Taiwan

3 Jun 2012

Early results from new PD-1 targeted immune therapy

Dr Suzanne Topalian - Johns Hopkins University School of Medicine, Baltimore, USA

2 Jun 2012

More from ecancer